1. Wu B, Bell K, Stanford A et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care. 2016 Apr 11;4(1):e000154.
2. Huang H, Shetty S, Bauer E et al. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease. Current Medical Research and Opinion 2017;1-7.
3. Tebboth A, Lee S, Scowcroft A et al. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice. Clin Ther. 2016 Aug;38(8):1825-1832.
4. Meyers JL1, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011 May;123(3):133-43.
5. Jentadueto SPC 22.6.2017 avsnitt 4.2 og 5.2.